S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
S&P 500   4,519.63 (+0.74%)
DOW   35,457.31 (+0.56%)
QQQ   375.47 (+0.76%)
AAPL   148.76 (+1.51%)
MSFT   308.23 (+0.31%)
FB   339.99 (+1.39%)
GOOGL   2,864.74 (+0.32%)
TSLA   864.27 (-0.67%)
AMZN   3,444.15 (-0.08%)
NVDA   222.90 (+0.31%)
BABA   177.00 (+6.10%)
NIO   40.03 (+1.06%)
CGC   14.34 (+8.64%)
GE   104.73 (+0.59%)
AMD   116.33 (-0.09%)
MU   67.57 (+0.46%)
T   25.59 (+1.03%)
F   15.42 (-0.90%)
ACB   7.45 (+7.66%)
DIS   171.18 (+0.02%)
PFE   42.09 (+1.86%)
BA   215.97 (-0.47%)
AMC   40.80 (-5.18%)
OTCMKTS:REPR

Repro-Med Systems Stock Forecast, Price & News

$2.75
-0.12 (-4.18 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.70
$2.85
50-Day Range
$2.73
$3.68
52-Week Range
$1.35
$4.26
Volume51,769 shs
Average Volume36,047 shs
Market Capitalization$109.69 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4
30 days | 90 days | 365 days | Advanced Chart
Receive REPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Repro-Med Systems and its competitors with MarketBeat's FREE daily newsletter.


About Repro-Med Systems

Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:REPR
Employees
75
Year Founded
N/A

Sales & Book Value

Annual Sales
$17.35 million
Cash Flow
$0.02 per share
Book Value
$0.23 per share

Profitability

Net Income
$910,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$109.69 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.21 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Repro-Med Systems (OTCMKTS:REPR) Frequently Asked Questions

What stocks does MarketBeat like better than Repro-Med Systems?

Wall Street analysts have given Repro-Med Systems a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Repro-Med Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Repro-Med Systems' earnings last quarter?

Repro-Med Systems, Inc. (OTCMKTS:REPR) released its quarterly earnings results on Tuesday, August, 6th. The company reported $0.00 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.02. The business earned $5.35 million during the quarter. Repro-Med Systems had a trailing twelve-month return on equity of 7.63% and a net margin of 0.17%.
View Repro-Med Systems' earnings history
.

How has Repro-Med Systems' stock price been impacted by Coronavirus (COVID-19)?

Repro-Med Systems' stock was trading at $8.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REPR stock has decreased by 68.1% and is now trading at $2.75.
View which stocks have been most impacted by COVID-19
.

Who are Repro-Med Systems' key executives?

Repro-Med Systems' management team includes the following people:
  • Mr. Daniel S. Goldberger, Exec. Chairman (Age 60)
  • Mr. Donald B. Pettigrew, CEO, Pres & Chief Commercial Officer (Age 51)
  • Ms. Karen Fisher, CFO, Treasurer & Corp. Sec. (Age 53)
  • Mr. Manuel A. Marques, Chief Operating Officer (Age 46)
  • Mr. Steven Kamphausen, Global VP of Sales & Marketing

What other stocks do shareholders of Repro-Med Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repro-Med Systems investors own include Globus Medical (GMED), Repro Med Systems (KRMD), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), ERYTECH Pharma (ERYP), Palatin Technologies (PTN), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), (CELG) and (CGC).

What is Repro-Med Systems' stock symbol?

Repro-Med Systems trades on the OTCMKTS under the ticker symbol "REPR."

How do I buy shares of Repro-Med Systems?

Shares of REPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repro-Med Systems' stock price today?

One share of REPR stock can currently be purchased for approximately $2.75.

How much money does Repro-Med Systems make?

Repro-Med Systems has a market capitalization of $109.69 million and generates $17.35 million in revenue each year.

How many employees does Repro-Med Systems have?

Repro-Med Systems employs 75 workers across the globe.

What is Repro-Med Systems' official website?

The official website for Repro-Med Systems is www.rmsmedicalproducts.com.

Where are Repro-Med Systems' headquarters?

Repro-Med Systems is headquartered at 24 CARPENTER RD, CHESTER NY, 10918.

How can I contact Repro-Med Systems?

Repro-Med Systems' mailing address is 24 CARPENTER RD, CHESTER NY, 10918. The company can be reached via phone at 845-469-2042 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.